NASDAQ: ATHE - Alterity Therapeutics Limited

Lønnsomhet i seks måneder: +73%
Sektor: Healthcare

Kampanjeplan Alterity Therapeutics Limited

Avansert tidsplan Enkel graf
Financial Markets by TradingView

Om selskapet

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease.

flere detaljer
It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Legg til i sammenligningslisten
Legg til overvåkningsliste
Legg til portefølje
Legg til prisvarsel

IPO date 2002-09-05
ISIN US02155X1063
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета aud
Сайт https://alteritytherapeutics.com
Цена ао 1.45
Prisendring per dag: -0.2858% (3.149)
Prisendring per uke: +42.73% (2.2)
Prisendring per måned: +188.07% (1.09)
Prisendring over 3 måneder: +136.98% (1.325)
Prisendring over seks måneder: +73% (1.815)
Prisendring per år: +26.1% (2.49)
Prisendring over 3 år: +256.01% (0.882)
Prisendring over 5 år: +204.85% (1.03)
Prisendring over 10 år: 0% (3.14)
Prisendring siden begynnelsen av året: +188.07% (1.09)
Alle parametere

Undervurdering

Navn Betydning Karakter
P/S 4.09 4
P/BV 1.19 9
P/E 0 0
EV/EBITDA -0.2025 0
Total: 5.38

Effektivitet

Navn Betydning Karakter
ROA, % -82.18 0
ROE, % -104.47 0
Total: 0

Utbytte

Navn Betydning Karakter
Div yield, % 0 0
DSI 0 0
Total: 0

Plikt

Navn Betydning Karakter
Debt/EBITDA -0.0081 10
Total: 9.6

Vekstimpuls

Navn Betydning Karakter
Lønnsomhet Revenue, % 876.58 10
Lønnsomhet Ebitda, % 89.99 9
Lønnsomhet EPS, % 31034.18 10
Total: 8.6
Flere detaljer

Institusjoner Volum Dele, %
Morgan Stanley 51485 0.7
Bank of Montreal/Can/ 14907 0.2
Twin Lakes Capital Management, LLC 5925 0.08
Providence Capital Advisors, LLC 200 0
Coppell Advisory Solutions, LLC 149 0
Osaic Holdings Inc 81 0
Sugarloaf Wealth Management, LLC 33 0
Steward Partners Investment Advisory, LLC 6 0



Veileder Stillingstittel Betaling Fødselsår
Mr. Geoffrey Paul Kempler B.Sc. Co-Founder & Non-Executive Chairman 207.52k 1955 (70 år)
Dr. David A. Stamler M.D. Chief Executive Officer 613.33k 1961 (64 år)
Dr. Rudolph Emile Tanzi Ph.D. Chief Scientific Advisor and Member of Research & Development Advisory Board N/A 1959 (66 år)
Dr. Robert Cherny Head of Research N/A
Mr. Phillip Allen Hains BBus(Acc), C.A., M.B.A. CFO & Company Secretary N/A 1959 (66 år)
Dr. Steven D. Targum M.D. Chief Medical Advisor

Adresse: Australia, Melbourne, 350 Collins Street - åpne i Google maps, åpne Yandex-kart
Nettsted: https://alteritytherapeutics.com